Since it has been shown that the most deleterious effects of hypertension occur in cerebral, renal and coronary vascular beds, it seems wise to evaluate these circulatory regions in relation to the effect of anti-hypertensive drugs.
Since it has been shown that the most deleterious effects of hypertension occur in cerebral, renal and coronary vascular beds, it seems wise to evaluate these circulatory regions in relation to the effect of anti-hypertensive drugs. Reports of the hemodynamic effects of Hydralazine4 on the renal (1-3) and cerebral (4, 5) circulations are already available, but comparable information is lacking in relation to the coronary circulation. Observations concerning coronary flow after the administration of Hydralazine are particularly desirable since it is known to precipitate angina pectoris in some patients (6) . The current report concerns an investigation of the cardiovascular hemodynamic effects of Hydralazine in subjects with arterial hypertension.
MATERIAL AND METHOD
Eleven hypertensive subjects from general medical wards were studied. Five of these subjects served as controls with determination of the various cardiac functions before and after administration of 1 cc. of saline solution.
Six served as experimental subjects with the same determinations made before and after Hydralazine. The determination of hemodynamic functions in this study was by the usual methods and has been reported previously from this laboratory (7) . The mined by the Fick principle. The catheter was then withdrawn from the pulmonary artery and placed in the coronary sinus for coronary blood flow determination. Approximately one-half hour after administration of either Hydralazine or saline through the cardiac catheter coronary blood flow determination was repeated. The catheter was then placed in the pulmonary artery and cardiac output was again determined. Thus each patient served as his own control, and the five patients who received the saline placebo served as controls for the method and procedure.
RESULTS
The results are seen in Table I . Significant changes occurred in the placebo (saline) group in only two of the determinations made. One was a slight fall in the body respiratory quotient and the other a slight fall in the mixed venous oxygen content. The reason for these two changes is not apparent, but it is of interest that their significance depends upon the consistency rather than the magnitude of change.
After administration of Hydralazine, hemodynamic changes occurred similar to those already reported by others (1, 3) and by this laboratory (7) . These changes included an increase in heart rate, a fall in systemic blood pressure and peripheral arterial resistance, a decreased arterial and mixed venous carbon dioxide content, and a smaller arteriovenous carbon dioxide difference. The change in cardiac index in this series was variable, as has already been reported (7) , but the mean average tended to increase following Hydralazine administration. Total body carbon dioxide production and oxygen consumption were unchanged and the respiratory quotient was constant. The hemodynamic data concerning these five patients were reported previously exclusive of the coronary metabolic data (7). Hydralazine 1-HYDRAZINOPHTHALAZINR AND CORONARY BLOOD FLOW produced an increase in coronary blood flow in five out of six subjects, the over-all increase being 34 per cent. Simultaneously, with the decrease in perfusion pressure, there was a fall in coronary vascular resistance (-35 per cent). The increased coronary blood flow was accompanied by a decrease in the arterial-coronary sinus oxygen difference, such that left ventricular oxygen utilization was unchanged.
it may be speculated that angina is precipitated only in those patients who have a fixed coronary vascular resistance, which cannot compensate for the decrease in perfusion pressure and therefore have a reduction in coronary flow. We did not observe such a response in this series. The possibility also exists that Hydralazine specifically alters myocardial oxidative metabolism so that available oxygen is not utilized and angina is precipitated by a metabolic block. DISCUSSION This study reveals that Hydralazine decreases coronary vascular resistance to such a degree that an increase in flow occurs in spite of the reduced perfusion pressure. Simultaneously, the arteriovenous oxygen difference across the myocardium narrows so that the left ventricular oxygen consumption per 100 g. remains unchanged. It was noted previously that the blood carbon dioxide levels were altered by the administration of Hydralazine (7) 
